Tango Therapeutics [TNGX] vs Regeneron [REGN] Detailed Stock Comparison

Tango Therapeutics Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Tango Therapeutics Inc. wins in 1 metrics, Regeneron Pharmaceuticals, Inc. wins in 16 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Tango Therapeutics Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 10.58 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 9.70 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -16.84 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -32.42 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -162.85% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -178.39% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -37.24% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -19.45% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-139.93M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 890.09% 25.39% Tango Therapeutics Inc.
Price-to-Sales Ratio (TTM) 62.29 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $3.53B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 56.66 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $1 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-0.87 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.32 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 32.51% 2.55% Regeneron Pharmaceuticals, Inc.

Tango Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

TNGX
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Tango Therapeutics Inc.-0.14%7.29%-5.33%86.47%113.29%140.76%
Regeneron Pharmaceuticals, Inc.2.66%-5.03%-15.02%-23.79%-18.77%-22.36%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Tango Therapeutics Inc.890.09%589.03%100.73%114.44%114.44%114.44%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Tango Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricTNGXREGN
Market Information
Market Cap i$3.73B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i2,955,573642,495
90 Day Avg. Volume i3,083,074617,765
Last Close$21.47$618.95
52 Week Range$2.45 - $28.41$476.49 - $821.11
% from 52W High-24.43%-24.62%
All-Time High$28.41 (Apr 21, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-24.43%-48.90%
Growth Metrics
Quarterly Revenue Growth-1.00%0.03%
Quarterly Earnings Growth-1.00%-0.08%
Financial Health
Profit Margin (TTM) i-1.63%0.31%
Operating Margin (TTM) i-1.78%0.23%
Return on Equity (TTM) i-0.37%0.15%
Debt to Equity (MRQ) i9.709.51
Cash & Liquidity
Book Value per Share (MRQ)$2.55$304.65
Cash per Share (MRQ)$2.41$83.86
Operating Cash Flow (TTM) i$-138,886,000$4.98B
Levered Free Cash Flow (TTM) i$-60,859,624$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Tango Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricTNGX (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-16.8414.21
PEG Ratio i-16.84-4.80
Price to Sales (TTM) i62.295.50
Price to Book (MRQ) i10.582.45
Market Capitalization
Market Capitalization i$3.73B$80.98B
Enterprise Value i$3.53B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i56.664.95
Enterprise to EBITDA i-32.4216.72
Risk & Other Metrics
Beta i1.320.40
Book Value per Share (MRQ) i$2.55$304.65

Financial Statements Comparison: Tango Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTNGX (2025)REGN (2025)
Revenue/Sales i62.38M14.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i0.0%14.6%
Gross Profit iN/A12.24B
Gross Margin i0.0%85.4%
Research & Development i132.17M5.85B
Operating Income (EBIT) i-111.29M3.70B
Operating Margin i-178.4%25.8%
EBITDA i-109.01M5.00B
EBITDA Margin i-174.7%34.8%
Pre-Tax Income i-101.59M5.23B
Pre-Tax Income % of Revenue i-162.8%36.5%
Income Tax i4,000725.80M
Income Tax % of Revenue i0.0%5.1%
Net Income (Profit) i-101.59M4.50B
Profit Margin i-162.9%31.4%

Balance Sheet & Liquidity Metrics

MetricTNGX (2025)REGN (2025)
Cash & Equivalents i112.28M3.12B
Total Current Assets i353.76M18.02B
Total Current Assets % of Revenue i567.1%125.7%
Total Current Liabilities i21.68M4.37B
Total Current Liabilities % of Revenue i34.8%30.5%
Long-Term Debt i30.83M2.71B
Long-Term Debt % of Revenue i49.4%18.9%
Total Shareholders Equity i346.18M31.26B
Retained Earnings i-603.15M35.80B
Retained Earnings % of Revenue i-966.8%249.6%
Property, Plant & Equipment i44.56M1.54B

Cash Flow Statement Comparison

MetricTNGX (2025)REGN (2025)
Operating Cash Flow i-135.54M6.30B
Operating Cash Flow % of Revenue i-217.3%43.9%
Capital Expenditures i-1.05M0
Free Cash Flow i-139.93M3.77B
FCF Margin i-224.3%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricTNGXREGN
Shares Short i40.37M2.55M
Short Ratio i9.954.46
Short % of Float i32.51%2.55%
Shares Outstanding i135.94M105.72M
Float Shares i67.70M98.55M
% Held by Insiders i1.38%1.98%
% Held by Institutions i119.95%91.08%
% Held by Public i-21.33%6.94%

Dividend Analysis & Yield Comparison: Tango Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricTNGXREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026